Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases.

Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.

Alexion's metabolic franchise includes a therapy for the treatment of hypophosphatasia (HPP), a systemic metabolic disease whose biochemical hallmark is low alkaline phosphatase (ALP) activity.

This article waslast modified on
March 1, 2018.